Finance

Beta
Lists
QIA:FRA
Qiagen NV
€30,00
-4,37%
(-1,37) 1D
2 Jun., 19:10:21 GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for QIA...
Open
€30,84
High
€31,35
Low
€30,00
Mkt. cap
6,14 mjd
Avg. vol.
1,83 k
Volume
450,00
Dividend
0,99%
Quarterly dividend
€0,07
Ex-dividend date
07 Jul. 2026
P/E ratio
18,52
52-wk high
€48,80
52-wk low
€27,86
EPS
€1,62
Shares outstanding
226,24 m
No. of employees
6 k
Open
€30,84
High
€31,35
Low
€30,00
Mkt. cap
6,14 mjd
Avg. vol.
1,83 k
Volume
450,00
Dividend
0,99%
Quarterly dividend
€0,07
Ex-dividend date
07 Jul. 2026
P/E ratio
18,52
52-wk high
€48,80
52-wk low
€27,86
EPS
€1,62
Shares outstanding
226,24 m
No. of employees
6 k
News stories
From sources across the web
Profile
QIAGEN N.V. is a German-founded multinational provider of sample and assay technologies for molecular diagnostics, applied testing, academic research, and pharmaceutical research. The company operates in more than 35 offices in over 25 countries. QIAGEN N.V., the global corporate headquarter of the QIAGEN group, is located in Venlo, The Netherlands. The main operative headquarters are located in Hilden, Germany. European, American, Chinese, and Asian-Pacific regional headquarters are located respectively in Hilden, Germany; Germantown, Maryland, United States; Shanghai, China; and Singapore. QIAGEN's shares are listed at the NYSE and at the Frankfurt Stock Exchange in the Prime Standard. Thierry Bernard is the company's Chief Executive Officer. Wikipedia
About Qiagen NV
CEOThierry Bernard
Employees5,5 k
Founded29 Nov. 1984
HeadquartersVenlo, Limburg, Nederland
SectorHealth care
Websiteqiagen.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun. 2025
Sep. 2025
Des. 2025
Mrt. 2026
Revenue
533,54 m
532,58 m
540,42 m
492,32 m
Cost of goods sold
185,95 m
187,78 m
173,92 m
168,83 m
Cost of revenue
185,95 m
187,78 m
173,92 m
168,83 m
Research and development expenses
47,75 m
48,75 m
47,24 m
48,26 m
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
148,74 m
143,11 m
153,88 m
142,39 m
Operating expense
211,62 m
207,51 m
218,30 m
206,24 m
Total operating expenses
397,57 m
395,29 m
392,22 m
375,06 m
Operating income
135,97 m
137,29 m
148,20 m
117,26 m
Other non operating income
-35,00 k
-89,00 k
-133,00 k
193,00 k
EBT including unusual items
126,82 m
134,73 m
109,17 m
85,83 m
EBT excluding unusual items
140,89 m
142,86 m
157,94 m
118,66 m
Income tax expense
30,57 m
4,68 m
1,34 m
17,79 m
Effective tax rate
24,11%
3,48%
1,23%
20,72%
Other operating expenses
-
-
-
-
Net income
96,25 m
130,04 m
107,83 m
68,04 m
Net profit margin
18,04%
24,42%
19,95%
13,82%
Earnings per share
0,63
-
0,62
0,54
Interest and investment income
13,86 m
15,07 m
20,00 m
10,56 m
Interest expense
-7,60 m
-8,22 m
-10,14 m
-11,05 m
Net interest expenses
6,25 m
6,85 m
9,86 m
-489,00 k
Depreciation and amortization charges
-
-
-
-
EBITDA
185,45 m
188,26 m
179,60 m
168,47 m
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer